In its latest quarterly filing, Indaptus Therapeutics announced the halt of patient enrollment in its Phase 1 Combination Study involving Decoy20 and checkpoint inhibitor Tislelizumab, with no current plans for new clinical trials. Concurrent executive management changes underscore organizational transition. The company’s immunotherapy platform, based on attenuated Gram-negative bacteria and protected by patents in multiple international jurisdictions, remains early-stage. Financial constraints and operational uncertainties present significant execution risks as Indaptus explores potential strategic transactions to sustain development and growth.